LL-37

LL-37 is a cathelicidin antimicrobial peptide — the only member of this important immune defense class expressed in humans. It is derived from the precursor protein hCAP-18, which is cleaved by protease enzymes in neutrophils and skin cells to release the active 37-amino acid LL-37 fragment. The name reflects its structure: "LL" for the two leucine residues at its N-terminus, and "37" for its amino acid length. LL-37 plays a fundamental role in innate immunity — the body's first-line defense system that operates before the adaptive immune response (antibodies and T-cells) can be mobilized.

The antimicrobial mechanism of LL-37 is direct membrane disruption. As an amphipathic helical peptide (meaning it has both hydrophilic and hydrophobic regions in a spiral structure), LL-37 inserts itself into bacterial cell membranes and forms pores that compromise membrane integrity, leading to osmotic collapse and bacterial death. This physical disruption mechanism means bacteria cannot develop resistance through the standard mutation-based pathways that defeat conventional antibiotics — bacteria would need to fundamentally change the composition of their cell membranes to evade LL-37, which is not evolutionarily feasible in the same way antibiotic resistance typically develops. LL-37 also disrupts the membranes of many viruses and fungi, giving it a broad-spectrum antimicrobial profile.

Beyond direct killing, LL-37 functions as an immunomodulatory signaling molecule. It activates toll-like receptors and formyl peptide receptors on immune cells, recruits neutrophils and monocytes to sites of infection, promotes dendritic cell maturation (enhancing adaptive immune response activation), and stimulates wound healing through promotion of keratinocyte migration and angiogenesis. Deficiency in LL-37 production has been directly linked to increased susceptibility to specific pathogens — patients with the rare condition of Specific Granule Deficiency who lack LL-37 suffer from recurrent and severe bacterial infections, confirming its non-redundant immune defense role.

Research interest has expanded significantly into LL-37's roles in gut microbiome regulation, inflammatory skin conditions (psoriasis, rosacea, atopic dermatitis), and cancer biology. Some cancers upregulate LL-37 as a survival mechanism, while others are inhibited by it — the dual role in cancer biology has generated substantial oncology research interest. For practical applications, topical LL-37 formulations have shown promising results in clinical trials for skin conditions characterized by inadequate antimicrobial peptide expression.